The ESMO congress always disseminates the latest ... EVP, EVERSANA COMPLETE Oncology, EVERSANA; Barry Vucsko, Senior Vice President, Client Services and Business Development Leader, EVERSANA ...

Over the next few years, the promise is that a broader field of immuno-oncology drugs will ... The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

This Industry Satellite Symposium was presented at the European Society for Medical Oncology (ESMO) Congress 2024, held in ...

Abstracts will be made available on the ESMO I-O website on 5 December 2024 at 00:05 CET. The poster containing new data, not in the abstract, will be available on the Posters & Publications section ...

Welcome to Medscape's ESMO 2017 Live Blog. Throughout the ESMO 2017 Congress in Madrid, experts from across a range of cancer tumor types will provide real-time coverage of the most important ...

In recent years, immuno-oncology has redefined cancer treatment by harnessing the body's immune system to fight cancer more effectively. With traditional treatments often falling short in advanced ...

The European Society for Medical Oncology holds an annual congress where scientists ... about the research our scientists have presented at the congress over the years. ESMO Virtual Plenary 2022: ...

The company is now advancing into immuno-oncology (IO), led by Timo van den Berg, Senior Director of Immuno-Oncology, and Wim Dokter, Chief Scientific Officer. Byondis’ lead cancer ...

additional monotherapy data expected in 1H 2025 -- -- Expect to present preclinical data on the combination potential of EO-3021 with VEGFR2 or PD-1 inhibitors at ESMO Immuno-Oncology Annual Congress ...

Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding ...